A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leukemia

A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leukemia

Alexander Gaiger (ORCID: 0000-0001-6340-3446)

Wissenschaftsdisziplinen

Gesundheitswissenschaften (30%); Klinische Medizin (50%); Medizinisch-theoretische Wissenschaften, Pharmazie (20%)

Keywords

    LEUKÄMIE, IMMUNTHERAPIE, VACCINE, BCR-ABL

Forschungsstätte(n)